Recent Updates
Recently added Catalysts
WVE Positive Sentiment

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

Key Takeaway: Wave Life Sciences is set to host a live webcast on July 30, 2025, to discuss its second quarter financial results and provide business updates. The company focuses on RNA medicines and has a diversified pipeline addressing various disorders, including Duchenne muscular dystrophy and Huntington's disease. The event will be accessible via their investor relations website.
Price reaction · baseline $7.93 (2025-07-22 close) · hit pre-market · clean, no other WVE news in the window
day 0 close · peak
+7.9%
day 1
+5.8%
day 3
+3.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Wave Life Sciences is advancing RNA medicines with a diversified pipeline.
  • The company is hosting a live event to discuss financial results and updates.
  • Wave's innovative PRISM platform offers unique capabilities in RNA therapeutics.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
33.2%
average across 9 past catalysts
Cash runway
~27 mo
Minimal dilution risk
Lead asset
WVE-N531
Phase 2 · Duchenne Muscular Dystrophy

Full Press Release Details

CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, July 30, 2025, to review the company’s second quarter 2025 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website:https://ir.wavelifesciences.com/events-publications/events.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing linkhere.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life SciencesWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visitwww.wavelifesciences.comand follow Wave onX(formerly Twitter) and LinkedIn.

Contact:Kate RauschVP, Corporate Affairs and Investor Relations+1 617-949-4827Investors:InvestorRelations@wavelifesci.com

Frequently Asked Questions

When will Wave Life Sciences announce Q2 2025 results?

Wave Life Sciences will announce its Q2 2025 results on July 30, 2025.

How can I access the Wave Life Sciences webcast?

The webcast can be accessed via the 'Investor Events' section on Wave's website.

What is the focus of Wave Life Sciences?

Wave Life Sciences focuses on RNA medicines to transform human health.

What disorders does Wave's pipeline address?

Wave's pipeline includes programs for Duchenne muscular dystrophy and Huntington's disease.

Last updated: Jul 23, 2025